Compare FPI & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | OMER |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.1M | 628.9M |
| IPO Year | 2014 | 2009 |
| Metric | FPI | OMER |
|---|---|---|
| Price | $10.07 | $10.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 550.8K | ★ 1.7M |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $52,990,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $2.95 |
| 52 Week High | $12.87 | $13.60 |
| Indicator | FPI | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 59.20 |
| Support Level | $9.65 | $9.31 |
| Resistance Level | $10.13 | $11.71 |
| Average True Range (ATR) | 0.14 | 0.67 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 90.91 | 51.11 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.